Next Article in Journal
Association of Marijuana Use and Cyclic Vomiting Syndrome
Next Article in Special Issue
The Chemical Components of Sesbania grandiflora Root and Their Antituberculosis Activity
Previous Article in Journal
Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
Open AccessReview

Chemotherapeutic Interventions Against Tuberculosis

1
Department of Laboratory Medicine and Pathology, 728-Heritage Medical Research Center, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2S2, Canada
2
Department of Pharmacy, Mangalayatan University, Beswan, Aligarh 202 145, India
3
Department of Surgery, 728-Heritage Medical Research Center, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2S2, Canada
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2012, 5(7), 690-718; https://doi.org/10.3390/ph5070690
Received: 15 May 2012 / Revised: 12 June 2012 / Accepted: 21 June 2012 / Published: 28 June 2012
(This article belongs to the Special Issue Antituberculosis Drugs)
Tuberculosis is the second leading cause of infectious deaths globally. Many effective conventional antimycobacterial drugs have been available, however, emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) has overshadowed the effectiveness of the current first and second line drugs. Further, currently available agents are complicated by serious side effects, drug interactions and long-term administration. This has prompted urgent research efforts in the discovery and development of new anti-tuberculosis agent(s). Several families of compounds are currently being explored for the treatment of tuberculosis. This review article presents an account of the existing chemotherapeutics and highlights the therapeutic potential of emerging molecules that are at different stages of development for the management of tuberculosis disease. View Full-Text
Keywords: tuberculosis chemotherapy; mycobacterium; drug-resistant tuberculosis; emerging TB drugs tuberculosis chemotherapy; mycobacterium; drug-resistant tuberculosis; emerging TB drugs
Show Figures

Figure 1

MDPI and ACS Style

Shakya, N.; Garg, G.; Agrawal, B.; Kumar, R. Chemotherapeutic Interventions Against Tuberculosis. Pharmaceuticals 2012, 5, 690-718.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop